Date: 2012-11-02
Type of information: Publication of results in a medical journal
phase: 2
Announcement: publication of results in the Journal of Crohn's and Colitis
Company: 4SC (Germany)
Product: vidofludimus
Action
mechanism: The therapeutic efficacy of vidofludimus is based on a dual principle. Vidofludimus inhibits the expression of selected pro-inflammatory cytokines, including interleukin-17 (IL-17A and IL-17F) and IFN-gamma that have crucial pathogenic roles in a variety of autoimmune diseases. Vidofludimus also inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme of the pyrimidine biosynthesis, thereby halting the proliferation of activated T and B cells which are involved in the pathology of autoimmune disorders.
Disease: inflammatory bowel disease
Crohn\'s disease
ulcerative colitis
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
Country:
Trial details:
Latest
news: 4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, has announced, that data from its clinical Phase II study with Vidofludimus in patients with inflammatory bowel disease (IBD), which was completed and reported last year, have been published online in Journal of Crohns & Colitis. "Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study". K.R. Herrlinger et al. Journal of Crohn's and Colitis. Volume 7, Issue 8 , Pages 636-643, 1 September 2013
In the open-label, clinical Phase IIa study, vidofludimus had been investigated in steroid-dependent patients with Crohn\'s disease and Ulcerative colitis. The compound was safe and well tolerated and showed a positive response rate in 88.5% of the patients by completely or partially reducing patients\' dependence on cortico-steroid drugs.
